mivalsecovatein

mivalsecovatein (NVX-CoV2373 XBB.1.5, NVX-CoV2601) is an adjuvanted, recombinant protein subunit COVID-19 vaccine developed by Novavax to target the SARS-CoV-2 Omicron XBB.1.5 subvariant. The vaccine consists of recombinant SARS-CoV-2 spike (S) glycoproteins stabilized in their prefusion conformation, which are formulated into nanoparticles. It is administered alongside Novavax's proprietary saponin-based Matrix-M adjuvant, which enhances the immune response by promoting the recruitment and activation of antigen-presenting cells at the injection site, leading to robust humoral and cellular immunity. mivalsecovatein is indicated for active immunization to prevent COVID-19 in individuals aged 12 years and older. In 2024, Novavax entered into a co-exclusive licensing agreement with Sanofi to commercialize the vaccine globally, except in regions with existing partnerships such as India (Serum Institute of India), South Korea (SK bioscience), and Japan (Takeda).

Brand names

Covovax XBB.1.5Nuvaxovid XBB.1.5

Other names

COVID-19 Vaccine (recombinant, adjuvanted) (SARS-CoV-2 Omicron XBB.1.5)COVID-19 Vaccine, Adjuvanted (2023-2024 Formula)SARS-CoV-2 rS Protein (COVID-19) Nanoparticle Vaccine, Omicron XBB.1.5 variant